Garen Bohlin, Director at Karyopharm Therapeutics, holds 18.52K shares in Karyopharm Therapeutics (Ticker: KPTI), holds 0.00 shares in Tetraphase (Ticker: TTPH), holds 71.00K shares in Collegium Pharmaceutical (Ticker: COLL).
Garen Bohlin latest transaction was an Uninformative Buy of ―.
What was Garen Bohlin's most profitable transaction?
Garen Bohlin’s most profitable transaction was an Informative Sell of COLL stock on May 13, 2026. The return on the trade was 34.70%.
What is Garen Bohlin's role in Karyopharm Therapeutics?
Garen Bohlin's role in Karyopharm Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.